PERRIGO Co plc
Perrigo is a self-care products company serving consumers and retail customers, primarily in North America and Europe. Its Consumer Self-Care Americas segment develops, manufactures and markets products in the U.S. and Canada, mainly store-brand products sold under customers’ brands, alongside a selection of Perrigo-owned brands. Consumer Self-Care International covers markets outside the U.S. and Canada, primarily Europe and Australia, with branded products and store brands. Products include treatments for respiratory, digestive, skin and women’s health needs, as well as nutrition, oral care, pain relief, vitamins and supplements. Brands include Mederma, Opill, Compeed, Solpadeine and ellaOne. Perrigo makes and sells products to retailers, wholesalers, pharmacies and other customers, and also markets products directly to consumers through certain platforms. Its headquarters are in Dublin 2, Ireland.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $PRGO in the last 30 days.
See all $PRGO insider activity →Perrigo (PRGO) updated its 2026 sales guidance, expecting a 5.7% to 4.6% year-over-year decline. The company reaffirmed its quarterly dividend, and its share price has risen 23.4% over the past 90 days to $15.85. Analysts have a consensus price target of $18, with estimates ranging from $15 to $20. Investors are evaluating whether the stock is undervalued given recent performance and guidance.
Perrigo Company plc set its 2026 adjusted diluted EPS outlook at $2.25 to $2.45, excluding its infant formula unit, which it classified as discontinued operations. Core EPS is expected at $2.15 to $2.35, with core sales declining 2.5% to 3.6% and an adjusted operating margin of 14% to 15%. The company plans to sell the unit to MeridianMade for up to $175 million, with $40 million upfront.
Perrigo (PRGO) reported Q3 earnings of $0.60 per share, beating estimates by $0.05, but revenue of $989M missed expectations and fell 5.2% YoY. Full-year 2026 EPS guidance was raised to $2.15-$2.35, above consensus. The company plans to sell its Infant Formula business for up to $175M, expecting an impairment loss of $275M-$375M in Q4. Shares rose 0.89% in pre-market trading.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning PRGO (PERRIGO Co plc). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent PRGO coverage spans earnings, mergers & acquisitions and financial news.
Guidance cut signals lower revenue growth, likely pressuring the stock lower.
Guidance downgrade and unit sale suggest lower near‑term revenue and cash flow.
Mixed earnings: EPS beat supports upside, revenue miss and divestiture risk weigh on price.
The cash offer is expected to lift Perrigo shares as shareholders receive a premium.
Commentary suggests mixed outlook; debt reduction is positive but management turmoil and buyout speculation create uncertainty.
AlphAI scores every news story that mentions PRGO with an AI model for sentiment and relevance, and aggregates insider trades from PERRIGO Co plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Perrigo (PRGO) updated its 2026 sales guidance, expecting a 5.7% to 4.6% year-over-year decline. The company reaffirmed its quarterly dividend, and its share price has risen 23.4% over the past 90 days to $15.85. Analysts have a consensus price target of $18, with estimates ranging from $15 to $20. Investors are evaluating whether the stock is undervalued given recent performance and guidance.
Perrigo Company plc set its 2026 adjusted diluted EPS outlook at $2.25 to $2.45, excluding its infant formula unit, which it classified as discontinued operations. Core EPS is expected at $2.15 to $2.35, with core sales declining 2.5% to 3.6% and an adjusted operating margin of 14% to 15%. The company plans to sell the unit to MeridianMade for up to $175 million, with $40 million upfront.
Perrigo (PRGO) reported Q3 earnings of $0.60 per share, beating estimates by $0.05, but revenue of $989M missed expectations and fell 5.2% YoY. Full-year 2026 EPS guidance was raised to $2.15-$2.35, above consensus. The company plans to sell its Infant Formula business for up to $175M, expecting an impairment loss of $275M-$375M in Q4. Shares rose 0.89% in pre-market trading.
MeridianMade, led by ByHeart co-founders Ron Belldegrun and Mia Funt, plans to acquire Dublin-based Perrigo for $175 million, with the sale expected to close in early 2027.
O'Keeffe Stevens Advisory's Q3 2026 investor letter highlights Perrigo (PRGO) as a top performer, up 42.1% in the quarter. The company's stock rebounded 12.5% in the past month, closing at $15.75 with a $2.18B market cap. Despite business challenges, including a 3% sales decline and 21% EPS drop, the firm notes potential for a turnaround and buyout rumors. PRGO's net debt is ~$2.9B, and it sold Dermacosmetics for ~$359M, reducing debt by $759M.
Canaccord Genuity maintained its Buy rating for Perrigo and increased its price target to $19 from $17, suggesting a 20.4% upside from the Oct 30 close of $15.78.
Perrigo Company plc (PRGO) announced a quarterly dividend of 29 cents per share, payable on December 15. The company is a provider of consumer self-care products and OTC health solutions. Payment is subject to board discretion and depends on earnings and financial conditions.
PERRIGO Co plc (PRGO) filed an SEC Form 8-K — Regulation FD Disclosure. Perrigo Announces Agreement to Divest Infant Formula Business to MeridianMade Advances Streamline pillar of Perrigo’s Three-S plan through portfolio simplification Furthers Perrigo’s evolution into a simpler, more focused consumer self-care company Expected to enhance Perri
Perrigo (PRGO) will sell its infant formula business to MeridianMade for up to $135 million, with $40 million at closing. The deal, expected to close in early 2027, aims to streamline Perrigo's portfolio, improve margins, and reduce future capital expenditures. Perrigo will record a non-cash impairment charge in Q4 2026.
Perrigo (PRGO) gained 3.77% on a $10M lawsuit settlement. Gilead (GILD) rose 3.8% after an analyst raised its price target. Kroger (KR) increased 3.87% despite 3K job cuts. Bristol-Myers (BMY) climbed 4.61% on positive drug trial results.
